Colby S. Shemesh

1.3k total citations · 1 hit paper
33 papers, 899 citations indexed

About

Colby S. Shemesh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Colby S. Shemesh has authored 33 papers receiving a total of 899 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Colby S. Shemesh's work include Cancer Immunotherapy and Biomarkers (11 papers), CAR-T cell therapy research (7 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Colby S. Shemesh is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), CAR-T cell therapy research (7 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Colby S. Shemesh collaborates with scholars based in United States, France and Switzerland. Colby S. Shemesh's co-authors include Anand Rotte, Sandhya Girish, Benjamin Wu, Joy Hsu, Patrick Twomey, Ben‐Quan Shen, Iraj Hosseini, Hailing Zhang, Hailing Zhang and Scott P. Henry and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Colby S. Shemesh

33 papers receiving 878 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study

2025 26 citations Richard Finn, Baek‐Yeol Ryoo et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Colby S. Shemesh

Since Specialization

Citations

This map shows the geographic impact of Colby S. Shemesh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colby S. Shemesh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colby S. Shemesh more than expected).

Fields of papers citing papers by Colby S. Shemesh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colby S. Shemesh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colby S. Shemesh. The network helps show where Colby S. Shemesh may publish in the future.

Co-authorship network of co-authors of Colby S. Shemesh

This figure shows the co-authorship network connecting the top 25 collaborators of Colby S. Shemesh. A scholar is included among the top collaborators of Colby S. Shemesh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colby S. Shemesh. Colby S. Shemesh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study breakdown → 2025 ·The Lancet Oncology ·Richard Finn, Baek‐Yeol Ryoo, (unknown), Daneng Li, Adam M. Burgoyne, (unknown), Shreya Badhrinarayanan, Yulei Wang, Anqi Yin, (unknown), Sami Mahrus, Matthew H. Secrest, Colby S. Shemesh, Nancy Xiaonan Yu, Stephen P. Hack, Edward Cha, Edward Gane	26
2	PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers 2024 ·British Journal of Cancer ·Rebecca Kristeleit, Alexandra Léary, Ana Oaknin, Andrés Redondo, Angela George, Jane Yuet Ching Hui, (unknown), Mario Liste-Hermoso, (unknown), Colby S. Shemesh, Jim Xiao, Kevin K. Lin, Luciana Molinero, Yinghui Guan, Isabelle Ray‐Coquard, Linda Mileshkin	12
3	Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103) 2023 ·The Journal of Clinical Pharmacology ·Elena Garralda, Do Youn Oh, Antoîne Italiano, Philippe L. Bédard, Jean‐Pierre Delord, Emiliano Calvo, Patricia LoRusso, Zev A. Wainberg, Andrés Cervantes, Alejo Rodríguez‐Vida, Colby S. Shemesh, Rucha Sane, Diana Mendus, Hao Ding, Robert L. Hendricks, (unknown), Byoung Chul Cho, Tae Won Kim, Benjamin M. Wu	9
4	Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework 2023 ·Clinical Pharmacology & Therapeutics ·Colby S. Shemesh, Phyllis Chan, Mathilde Marchand, António Gonçalves, Shweta Vadhavkar, Benjamin Wu, Chunze Li, Jin Y. Jin, Stephen P. Hack, René Bruno	4
5	395P Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC) 2023 ·Annals of Oncology ·Kyung Hae Jung, Stephen J. Luen, Mafalda Oliveira, Joohyuk Sohn, S-A Im, Seth A. Wander, Sara A. Hurvitz, Amir Sonnenblick, (unknown), (unknown), (unknown), Huy Ngo, Richard B. Schwab, Colby S. Shemesh, Jia Zhu, (unknown)	1
6	Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform 2023 ·The Oncologist ·Andrew H. Ko, Kyu‐pyo Kim, Jens T. Siveke, Charles D. Lopez, Jill Lacy, Eileen M. O’Reilly, Teresa Macarulla, Gulam A. Manji, Yong‐Seok Jee, Jaffer A. Ajani, María Maqueda, Sun Young Rha, Janet Lau, N. Al-Sakaff, Simon Allen, (unknown), Colby S. Shemesh, Xinxin Gan, Edward Cha, Do‐Youn Oh	37
7	Applying Natural Language Processing to ClinicalTrials.gov: mRNA cancer vaccine case study 2023 ·Clinical and Translational Science ·Bianca Vora, (unknown), (unknown), (unknown), Colby S. Shemesh, Gillie A. Roth	5
8	Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors 2022 ·Frontiers in Pharmacology ·Weize Huang, Felix Stader, Phyllis Chan, Colby S. Shemesh, Yuan Chen, Katherine L. Gill, Hannah M. Jones, Linzhong Li, Gianluca Rossato, Benjamin Wu, Jin Y. Jin, Pascal Chanu	6
9	Abstract CT185: Assessment of the impact of anti-drug antibodies on PK and clinical outcomes with atezolizumab + bevacizumab in HCC 2021 ·Cancer Research ·Peter R. Galle, Richard S. Finn, Ann‐Lii Cheng, Coen Bernaards, Colby S. Shemesh, (unknown), Wendy Verret, S Stanzel, (unknown), Michel Ducreux, Andrew X. Zhu	4
10	1315P Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer) 2020 ·Annals of Oncology ·Enriqueta Felip, (unknown), Melissa L. Johnson, Mary O’Brien, Fabrice Barlési, Julien Mazières, Benjamin Solomon, Víctor Moreno, Valentina Boni, Aurélie Swalduz, Sarah B. Goldberg, Bhumsuk Keam, Steven G. Allen, (unknown), Colby S. Shemesh, (unknown), N. Al-Sakaff, (unknown), Pakeeza Sayyed, Byoung Chul Cho	6
11	Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma 2020 ·Cancer Chemotherapy and Pharmacology ·Colby S. Shemesh, Priya Agarwal, Tong Lu, Calvin Lee, Randall Dere, Xiaobin Li, Chunze Li, Jin Y. Jin, Sandhya Girish, Dale Miles, Dan Lü	11
12	Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma 2020 ·Pharmaceutical Research ·Dan Lü, Tong Lu, (unknown), Leonid Gibiansky, Priya Agarwal, Colby S. Shemesh, Randall Dere, Uzor C. Ogbu, Jamie Hirata, Pascal Chanu, Sandhya Girish, Jin Y. Jin, Chunze Li, Dale Miles	13
13	SO-4 phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS–pancreatic ductal adenocarcinoma 2020 ·Annals of Oncology ·Vincent Chung, Angela Alistar, Ben George, (unknown), Hedy L. Kindler, Do‐Youn Oh, Simon Allen, Hila Barak, (unknown), (unknown), (unknown), Colby S. Shemesh, Volker Teichgräber, (unknown), Charles D. Lopez	6
14	Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities 2020 ·Molecular Therapy ·Colby S. Shemesh, Joy Hsu, Iraj Hosseini, Ben‐Quan Shen, Anand Rotte, Patrick Twomey, Sandhya Girish, Benjamin Wu	188
15	Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study 2019 ·The Lancet Oncology ·Birgit Geoerger, C. Michel Zwaan, Lynley V. Marshall, Jean Michon, Franck Bourdeaut, Michela Casanova, Nadège Corradini, Gianluca Rossato, Mufiza Farid‐Kapadia, Colby S. Shemesh, Katherine E. Hutchinson, Francis Donaldson, Minlei Liao, Hubert Caron, Tanya Trippett	105
16	Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer 2019 ·Journal for ImmunoTherapy of Cancer ·Colby S. Shemesh, Pascal Chanu, Kris M. Jamsen, (unknown), Gianluca Rossato, Francis Donaldson, Amit Garg, Helen Winter, Jane Ruppel, Xin Wang, René Bruno, Jin Jin, Sandhya Girish	36
17	Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2′-MOE-ASOs 2017 ·Molecular Therapy — Nucleic Acids ·Colby S. Shemesh, Rosie Z. Yu, Mark S. Warren, Michael Liu, (unknown), Brandon Nichols, Noah Post, Song Lin, Daniel A. Norris, Eunju Hurh, (unknown), Tanya Watanabe, Scott P. Henry, Yanfeng Wang	27
18	Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys 2016 ·Molecular Therapy — Nucleic Acids ·Colby S. Shemesh, Rosie Z. Yu, Hans Gaus, Sarah Greenlee, Noah Post, Karsten Schmidt, Michael T. Migawa, Punit P. Seth, Thomas A. Zanardi, Thazha P. Prakash, Eric E. Swayze, Scott P. Henry, Yanfeng Wang	46
19	Indocyanine green loaded liposome nanocarriers for photodynamic therapy using human triple negative breast cancer cells 2014 ·Photodiagnosis and Photodynamic Therapy ·Colby S. Shemesh, Claire Hardy, David S. Yu, Brian Fernández, Hailing Zhang	57
20	Thermosensitive Liposome Formulated Indocyanine Green for Near-Infrared Triggered Photodynamic Therapy: In Vivo Evaluation for Triple-Negative Breast Cancer 2014 ·Pharmaceutical Research ·Colby S. Shemesh, (unknown), Hailing Zhang	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact